PT - JOURNAL ARTICLE AU - Dispinseri, Stefania AU - Marzinotto, Ilaria AU - Brigatti, Cristina AU - Pirillo, Maria Franca AU - Tolazzi, Monica AU - Bazzigaluppi, Elena AU - Canitano, Andrea AU - Borghi, Martina AU - Gallinaro, Alessandra AU - Caccia, Roberta AU - Vercesi, Riccardo AU - McKay, Paul F AU - Ciceri, Fabio AU - Piemonti, Lorenzo AU - Negri, Donatella AU - Cinque, Paola AU - Cara, Andrea AU - Lampasona, Vito AU - Scarlatti, Gabriella TI - Seasonal betacoronavirus antibodies expansion post BNT161b2 vaccination associates with reduced SARS-CoV-2 VoCs neutralization AID - 10.1101/2021.08.15.21262000 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.15.21262000 4099 - http://medrxiv.org/content/early/2021/08/17/2021.08.15.21262000.short 4100 - http://medrxiv.org/content/early/2021/08/17/2021.08.15.21262000.full AB - SARS-CoV-2 vaccination is known to induce antibodies that recognize also variants of concerns (VoCs) of the virus. However, epidemiological and laboratory evidences indicate that these antibodies have a reduce neutralization ability against VoCs. We studied binding and neutralizing antibodies against the Spike RBD and S2 domains of the Wuhan-Hu-1 virus and its alpha and beta VoCs and of seasonal betacoronaviruses (HKU1 and OC43) in a cohort of 31 health care workers vaccinated with BNT162b2-Comirnaty and prospectively followed post-vaccination. The study of sequential samples collected up to 64 days post-vaccination showed that serological assays measuring IgG against Wuhan-Hu-1 antigens were a poor proxy for VoCs neutralization. In addition, in subjects who had asymptomatic or mild COVID-19 prior to vaccination the loss of nAbs following disease can be rapid and protection from re-infection post-vaccination is often no better than in naïve subjects. Interestingly, in health care workers naïve for SARS-CoV-2 infection, vaccination induced a rapid and transient reactivation of pre-existing seasonal coronaviruses IgG responses that was associated with a subsequent reduced ability to neutralize some VoCs.Competing Interest StatementLorenzo Piemonti and Vito Lampasona have a patent pending that refers to polypeptides, nucleic acids, vectors and host cells and their use in the diagnosis and/or treatment of COVID-19 infections. All other authors have declared that no conflict of interest exists.Clinical TrialClinicalTrialsgov-NCT04318366Funding StatementThe work performed at IRCCS Ospedale San Raffaele (OSR) was funded by Program Project COVID-19 OSR-UniSR and Ministero della Salute (COVID-2020-12371617). The work by Viral Evolution and Transmission Unit, OSR, Istituto Superiore di Sanità(ISS) and Imperial College was funded by EAVI2020, the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681137. ISS received support in part by NATO multi-year Project No. G5817 New and Validated Tools for the Diagnosis and follow-up of SARS-CoV-2 Infected Individuals, and by ISS internal funds. We thank Fondation Dormeur, Vaduz for the donation of laboratory instruments relevant to this project to the Viral Evolution and Transmission Unit at OSR and to the National Center for Global Health at the Istituto Superiore di Sanità.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study subjects belonged to the IRCCS Ospedale San Raffaele COVID-19 cohort study COVID-BioB (registered as ClinicalTrialsgov-NCT04318366) and approved by the IRCCS Ospedale San Raffaele Ethics Review Board (protocol 68/INT/2020) and the COVID-BioB related immunological sub-studies "Role of the immune response in the infection with SARS-CoV-2 and in the pathogenesis of COVID-19" (protocol number 34/int/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data that support the findings of this study are available upon reasonable request.